ARGENX SE (ARGX)
D
Pipeline Grade
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase2 Readout | — |
| 2026-09-01 | Phase3 Readout | — |
| 2026-09-30 | Phase3 Readout | — |
| 2026-10-01 | Phase3 Readout | — |
| 2026-11-01 | Phase2 Readout | — |
| 2026-12-01 | Phase3 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
| 2026-12-01 | Phase1 Readout | — |
| 2026-12-31 | Phase1 Readout | — |
| 2027-01-06 | Phase3 Readout | — |
| 2027-02-01 | Phase2 Readout | — |
| 2027-03-01 | Phase1 Readout | — |
| 2027-03-01 | Phase3 Readout | — |
| 2027-04-30 | Phase2 Readout | — |
| 2027-05-15 | Phase1 Readout | — |
| 2027-07-01 | Phase3 Readout | — |
Active Clinical Trials (42)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06860633 | Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod | PHASE4 | Recruiting | 20 |
| NCT06078553 | A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN,... | OTHER | Recruiting | 100 |
| NCT07595653 | A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasth... | OTHER | Recruiting | 100 |
| NCT06909214 | A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis... | PHASE4 | Recruiting | 30 |
| NCT06299748 | A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod Dur... | OTHER | Recruiting | 279 |
| NCT07264426 | Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study | OTHER | Recruiting | 200 |
| NCT06298565 | A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa | OTHER | Recruiting | 680 |
| NCT07294170 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip... | OTHER | Recruiting | 70 |
| NCT05152238 | ITP Registry and Accompanying Biospecimen Collection | OTHER | Recruiting | 1,100 |
| NCT05988073 | A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy | OTHER | Active Not Recruiting | 413 |
| NCT04833894 | Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children Wit... | PHASE3 | Recruiting | 12 |
| NCT05523167 | A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Infl... | PHASE3 | Active Not Recruiting | 265 |
| NCT06765161 | Efgartigimod in IVIG Dependent Myasthenia Gravis Patients | PHASE3 | Recruiting | 30 |
| NCT06544499 | A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia | PHASE3 | Recruiting | 69 |
| NCT06298552 | A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding A... | PHASE3 | Active Not Recruiting | 119 |
| NCT06558279 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | PHASE3 | Active Not Recruiting | 141 |
| NCT06684847 | A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome | PHASE3 | Active Not Recruiting | 631 |
| NCT04812925 | A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Imm... | PHASE3 | Active Not Recruiting | 173 |
| NCT07194850 | A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopen... | PHASE3 | Recruiting | 24 |
| NCT06392386 | A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | PHASE3 | Recruiting | 12 |
| NCT05979441 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active ... | PHASE3 | Enrolling By Invitation | 240 |
| NCT06742190 | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy | PHASE3 | Active Not Recruiting | 154 |
| NCT07596849 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease. | PHASE3 | Recruiting | 230 |
| NCT06920004 | A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP | PHASE3 | Recruiting | 218 |
| NCT07091630 | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | PHASE3 | Recruiting | 160 |
| NCT05374590 | Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously... | PHASE3 | Enrolling By Invitation | 12 |
| NCT04023526 | A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidat... | PHASE2 | Active Not Recruiting | 103 |
| NCT06655155 | A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | PHASE2 | Recruiting | 81 |
| NCT07284420 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With ... | PHASE2 | Recruiting | 70 |
| NCT06453694 | Efgartigimod for the Treatment of Acute Optic Neuritis | PHASE2 | Recruiting | 20 |
| NCT04280718 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic... | PHASE2 | Active Not Recruiting | 229 |
| NCT05907096 | ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function | PHASE2 | Active Not Recruiting | 103 |
| NCT06284954 | A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | PHASE2 | Active Not Recruiting | 3 |
| NCT05405361 | A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and... | PHASE2 | Active Not Recruiting | 51 |
| NCT07287982 | A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration... | PHASE2 | Recruiting | 60 |
| NCT06503731 | A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant ... | PHASE2 | Active Not Recruiting | 33 |
| NCT06441682 | A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | Active Not Recruiting | 60 |
| NCT07377396 | A Study to Assess the Safety of ARGX-124 in Healthy Volunteers | PHASE1 | Recruiting | 104 |
| NCT06436742 | A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myastheni... | PHASE1 | Recruiting | 16 |
| NCT07612020 | A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokin... | PHASE1 | Recruiting | 130 |
| NCT04150887 | Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia | PHASE1 | Active Not Recruiting | 61 |
| NCT07673601 | A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participan... | PHASE1 | Recruiting | 52 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.